Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Summary
The goal of this observational study is to determine how often lymph node metastases occur in the splenic hilum and surrounding fat in patients with left-sided pancreatic cancer. The main question the study aims to answer is: Is spleen removal necessary in all cases, or is the risk of lymph node metastases in the fat around the spleen low enough to reconsider this standard practice? Currently, spleen removal is part of the standard treatment for patients with left-sided pancreatic cancer to ensure that any potential lymph node metastases in the surrounding fat are also removed. However, the likelihood of metastases in this area is low, and spleen removal carries risks. This study is a first step toward changing the treatment approach. If the findings show that metastases in the fat around the spleen are rare, the next step will be a randomized trial to further investigate whether spleen removal is necessary.
Official title: Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID): Study Protocol for a Prospective Observational International Multicenter Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
94
Start Date
2024-11-28
Completion Date
2031-01-01
Last Updated
2025-09-05
Healthy Volunteers
No
Locations (10)
BenQ Hospital
Nanjing, China
Konstantopoulio General Hospital
Athens, Greece
Padova University Hospital
Padova, Italy
Kyushu University Hospital
Fukuoka, Japan
Amsterdam UMC
Amsterdam, Netherlands
OLVG Hospital
Amsterdam, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Oslo University Hospital
Oslo, Norway
Dr. Peset University Hospital
Valencia, Spain
Linköping University Hospital
Linköping, Sweden